D.C. Mun. Regs. tit. 22, r. 22-B1203
Current through Register Vol. 71, No. 49, December 6, 2024
Rule 22-B1203 - SCHEDULE III ENUMERATED1203.1 The controlled substances listed in this section are included in Schedule III of the Act unless removed therefrom pursuant to Section 201 of the Act:
(a) Schedule III shall consist of the following controlled substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section: (1) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric), and salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) The compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971 as excepted compounds under Title 21 § 1308.32 of the Code of Federal Regulations (C.F.R.), and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;(2) Depressants: Unless listed in another schedule, any material compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with depressant effect on the central nervous system: (A) Any compound, mixture, or preparation containing: (iv) Butabarbital (secbutabarbital);(vi) Butobarbital (butethal);(viii) Pentobarbital; or any salt thereof and one (1) or more other active medicinal ingredients which are not listed in any schedule;(B) Any suppository dosage form containing: (iv) Butabarbital (secbutabarbital);(vi) Butobarbital (butethal);(vii) Pentobarbital; or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;(C) Any substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid:(iii) Any drug product containing gamma-hydroxybutric acid including its salts, isomers, and salts of isomers.(vi) Lysergic acid amide;(viii) Sulfondiethylmethane;(xi) Tiletamine & Zolazepam Combination Product;(4) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: (A) Not more than one and eight-tenths (1.8) grams of codeine per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;(B) Not more than one and eight-tenths (1.8) grams of codeine per one hundred (100) milliliters or not more than ninety (90) milligrams dosage unit, with one (1) or more active non-narcotic ingredients in recognized therapeutic amounts;(C) Not more than three hundred (300) milligrams of dihydrocodeinone per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with a 4-fold or greater quantity of an isoquinoline alkaloid of opium;(D) Not more than three hundred (300) milligrams dihydrocodeine per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts;(E) Not more than one and eight-tenths (1.8) grams of dihydrocodeine per milliliters or not more than ninety (90) milligrams per dosage unit, with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts;(F) Codeine and isoquinoline alkaloid ninety (90) milligrams per dosage unit;(G) Codeine combination product ninety (90) milligrams per dosage unit;(H) Dihydrocodeine combination product ninety (90) milligrams per dosage unit;(I) Ethylmorphine combination product fifteen (15) milligrams per dosage unit;(J) Hydrocodone and isoquinoline alkaloid less than fifteen (15) milligrams per dosage unit;(K) Hydrocodone combination product less than fifteen (15) milligrams per dosage unit;(L) Not more than three hundred (300) milligrams of ethylmorphine per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with one (1) or more ingredients in recognized therapeutic amounts;(M) Not more than five hundred (500) milligrams of opium per one hundred (100) milliliters or per one hundred (100) grams or not more than twenty-five (25) milligrams per dosage unit, with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts;(N) Opium combination product twenty-five (25) milligrams per dosage unit;(O) Not more than fifty (50) milligrams of morphine per one hundred (100) milliliters or per one hundred (100) grams with one (1) or more active, non-narcotic ingredients in recognized therapeutic amounts; and(P) Any material, compound, mixture, or preparation containing Buprenorphine or its salts;(5) Anabolic Steroids: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, drug, or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progesterons, and corticosteroids) that promotes muscle growth and includes: (A) Boldenone (17beta-hydroxyandrost-1,4-diene-3-one);(B) Chlortestosterone (4-chlortestosterone);(C) Clostebol(4-chloro-17beta-hydroxyandrost-4-en-3-one);(D) Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one);(E) Delta1-dihydrotestosterone (17beta-hydroxy-5alpha androst-1-en-3-one);(F) Drostanolone(17beta-hydroxy-2alpha-methyl- 5alphaandrostan-3-one);(G) Ethylestrenol(17alpha-ethyl-17beta-hydroxyestr-4-ene);(H) Fluoxymesterone (9-fluoro-17alpha-methy 11beta,17beta- dihydroxyandrost-4-en-3-one);(I) Formebulone (formebolone);(2-formyl-17alpha- methyl11alpha,17beta-dihydroxyandrost-1,4-dien-3-one);(J) Furazabol(17alpha-methyl- 17betahydroxyandrostano [2,3-c]-furazan);(K) Mesterolone; (1alpha-methyl-17beta-hydroxy-5alphaandrostan-3-one);(L) Methandienone(17alpha-methyl-17betahydroxyandrost- 1,4-diene-3-one);(M) Methandriol (17alpha-methyl-3beta, 17betadihydroxyandrost-5-ene) (a.k.a. Methandrostenolone);(N) Methenolone (1-methyl-17beta-hydroxy-5alpha-androst1-en-3-one);(O) Methyltestosterone (17alpha-methyl-17betahydroxyandrost-4-en-3-one);(P) Mibolerone (7alpha,17alpha-dimethyl-17betahydroxyestr-4-en-3-one);(Q) Nandrolone (17beta-hydroxyestr-4-en-3-one);(R) Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4en-3-one);(S) Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa5alpha-androstan-3-one);(T) Oxymesterone (17alpha-methyl-4, 17betadihydroxyandrost-4-en-3-one);(U) Oxymetholone (17alpha-methyl-2-hydroxymethylene17beta-hydroxy-5alpha-androstan-3-one);(W) Stanozolol (17alpha-methyl-17beta-hydroxy-5alpha androst-2-eno[3,2-c]-pyrazole);(X) Testolactone (13-hydroxy-3-oxo- 13,17-secoandrosta 1,4-dien-17-oic acid lactone);(Y) Testosterone (17beta-hydroxyandrost-4-en-3-one);(Z) Trenbolone (17beta-hydroxyestr-4,9,11-trien-3- one);(AA) 13[BETA]-ethyl-17[BETA]-hydroxygon-4-en-3-one;(BB) 17[ALPHA]-methyl-3[ALPHA],17[BETA]-dihydroxy-5a-androstane;(CC) 17[ALPHA]-methyl-3[BETA],17[BETA]-dihydroxy-5a-androstane;(DD) 17[ALPHA]-methyl-3[BETA],17[BETA]-dihydroxyandrost-4-ene;(EE) 17[ALPHA]-methyl-4-hydroxynandrolone (17[ALPHA]-methyl-4- hydroxy-17[BETA]-hydroxyestr-4-en-3-one);(FF) 17[ALPHA]-methyl-[DELTA]1-dihydrotestosterone (17[BETA]-hydroxy-17[ALPHA]-methyl-5[ALPHA]-androst-1-en-3-one) (a.k.a. '17-[ALPHA]-methyl-1-testosterone');(GG) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);(HH) 19-nor-4-androstenediol (3[ALPHA], 17[BETA]-dihydroxyestr- 4-ene);(II) 19-nor-4-androstenediol (3[BETA], 17[BETA]-dihydroxyestr- 4-ene);(JJ) 19-nor-4-androstenedione (estr-4-en-3,17-dione);(KK) 19-nor-5-androstenediol (3[ALPHA], 17[BETA]-dihydroxyestr- 5-ene);(LL) 19-nor-5-androstenediol (3[BETA], 17[BETA]-dihydroxyestr- 5-ene);(MM) 19-nor-5-androstenedione (estr-5-en-3,17-dione);(NN) 1-androstenediol (3[ALPHA],17[BETA]-dihydroxy-5[ALPHA]-androst- 1-ene);(OO) 1-androstenediol (3[BETA],17[BETA]-dihydroxy-5[ALPHA]-androst- 1-ene);(PP) 1-androstenedione ([5[ALPHA]]-androst-1-en-3,17-dione);(QQ) 3[ALPHA],17[BETA]-dihydroxy-5a-androstane;(RR) 3[BETA],17-dihydroxy-5a-androstane;(SS) 4-androstenediol (3[BETA],17[BETA]-dihydroxy-androst-4-ene);(TT) 4-androstenedione (androst-4-en-3,17-dione);(UU) 4-dihydrotestosterone (17[BETA]-hydroxy-androstan- 3-one);(VV) 4-hydroxy-19-nortestosterone (4,17[BETA]-dihydroxy- estr-4-en-3-one);(WW) 4-hydroxytestosterone (4,17[BETA]-dihydroxy-androst- 4-en-3-one);(XX) 5-androstenediol (3[BETA],17[BETA]-dihydroxy-androst-5-ene);(YY) 5-androstenedione (androst-5-en-3,17-dione);(ZZ) Androstanedione 5[ALPHA]-androstan-3,17-dione;(AAA) Bolasterone (7[ALPHA],17[ALPHA]-dimethyl-17[BETA]-hydroxyandrost-4-en-3-one);(BBB) Boldione (androsta-1,4-diene-3,17-dione);(CCC) Calusterone (7[BETA],17[ALPHA]-dimethyl-17[BETA]-hydroxyandrost-4-en-3-one);(DDD) Desoxymethyltestosterone (17[ALPHA]-methyl-5[ALPHA]- androst-2-en-17[BETA]-ol) (a.k.a. 'madol');(EEE) Furazabol (17[ALPHA]-methyl-17[BETA]-hydroxyandrostano[2,3-c]-furazan);(FFF) Mestanolone (17[ALPHA]-methyl-17[BETA]-hydroxy- 5-androstan-3-one);(GGG) Methasterone (2[ALPHA],17[ALPHA]-dimethyl-5[ALPHA]-androstan- 17[BETA]-ol-3-one);(HHH) Methyldienolone (17[ALPHA]-methyl-17[BETA]-hydroxyestra-4,9(10)-dien-3-one);(III) Methyltrienolone (17[ALPHA]-methyl-17[BETA]-hydroxyestra-4,9,11-trien-3-one);(JJJ) Norbolethone (13[BETA], 17[ALPHA]-diethyl-17[BETA]-hydroxygon- 4-en-3-one);(KKK) Norclostebol (4-chloro-17[BETA]-hydroxyestr- 4-en-3-one);(LLL) Normethandrolone (17[ALPHA]-methyl-17[BETA]-hydroxyestr- 4-en-3-one);(MMM) Prostanozol (17[BETA]-hydroxy-5[ALPHA]-androstano[3,2-c]pyrazole);(NNN) Stenbolone (17[BETA]-hydroxy-2-methyl-[5[ALPHA]]-androst-1-en-3-one);(OOO) Tetrahydrogestrinone (13[BETA], 17[ALPHA]-diethyl-17[BETA]-hydroxygon- 4,9,11-trien-3-one)(PPP) [DELTA]1-dihydrotestosterone (a.k.a.'1-testosterone') (17[BETA]-hydroxy-5[ALPHA]-androst-1-en-3-one); and(QQQ) Any salts, ester or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except the term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses or distributes that steroid for human use the person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph.,(6) Hallucinogenic substances;(7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product. [Some other names for dronabinol: 6aR-trans)-6a,7,8,10a-tetrahydro- 6,6,9- trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-o1] or (-)-delta-9-(trans)-tetrahydrocannabinol]; and(b) The Mayor may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraphs (1) and (2) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains one (1) or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiates the potential for abuse of the substances that have a stimulant or depressant effect on the central nervous system.D.C. Mun. Regs. tit. 22, r. 22-B1203
Final Rulemaking published at 39 DCR 1882, 1888 (March 20, 1992); as amended by Final Rulemaking published at 41 DCR 7967 (December 16, 1994); Notice of Emergency and Proposed Rulemaking published at 47 DCR 7512 (September 15, 2000) [EXPIRED]; as amended by Final Rulemaking published at 48 DCR 914 (February 2, 2001); as amended by Notice of Emergency and Proposed Rulemaking published at 50 DCR 10421 (December 5, 2003) [EXPIRED]; as amended by Final Rulemaking published at 51 DCR 4080 (April 23, 2004); as amended by Final Rulemaking published at 61 DCR 10233 (October 3, 2014); Final Rulemaking published at 39 DCR 1882, 1888 (March 20, 1992); as amended by Final Rulemaking published at 41 DCR 7967 (December 16, 1994); Notice of Emergency and Proposed Rulemaking published at 47 DCR 7512 (September 15, 2000) [EXPIRED]; as amended by Final Rulemaking published at 48 DCR 914 (February 2, 2001); as amended by Notice of Emergency and Proposed Rulemaking published at 50 DCR 10421 (December 5, 2003) [EXPIRED]; as amended by Final Rulemaking published at 51 DCR 4080 (April 23, 2004); as amended by Final Rulemaking published at 61 DCR 10233 (October 3, 2014)